Builders FirstSource heads into tomorrow's Q2 results with short sellers actively covering and analysts trimming targets — two signals pulling in opposite directions ahead of the print.
The most notable shift in positioning is the rapid unwind of short interest. Bears have cut exposure by roughly 20% over the past month, bringing SI down to 6.1% of the free float from above 8.4% in early July. That move accelerated this week, with the short base falling another 7% over five sessions. Borrow conditions confirm the retreat: availability has widened sharply to 1,576% — more than 15 shares available for every one currently borrowed — with cost to borrow easing to just 0.38%. Short sellers are not building pressure into this earnings event; they are exiting it.
Options positioning echoes that lack of conviction either way. The put/call ratio is running slightly above its 20-day average at 0.59, but the z-score barely reaches 0.86 — well inside normal range. With the 52-week PCR high at 1.13, there is no sign of the kind of defensive hedging that often precedes a feared earnings release. The stock itself is up 5.6% on the week to $73.68, though it remains down 17% over the past month, a pattern consistent with a stock that sold off hard and has since stabilised ahead of a catalyst.
The analyst community has spent the past week lowering targets without abandoning ratings. BMO trimmed to $85 on Tuesday while holding Market Perform; Benchmark and Oppenheimer both cut targets last week but kept Buy and Outperform calls respectively. Across the broader post-Q1 reset, targets from Barclays, RBC, and Wells Fargo all moved lower in May after the last quarterly print, which saw BLDR fall 9.2% on the day and a further 4.8% over the following week. The consensus mean now sits at $96.52, implying roughly 31% upside from current levels — generous, but reflecting a Street that believes the valuation discount already captures the housing downturn. Bulls point to BLDR's custom product capabilities and market position in a fragmented industry as a floor beneath earnings, while bears note that NTM EBITDA estimates are running roughly 30% below the company's historical normalised average, with credit availability and material cost pressures still unresolved. The P/E has contracted roughly 3.3 points over 30 days to 14x, and price-to-book has fallen by 0.4 turns over the same period — meaningful multiple compression for a company the bulls argue is nearing a trough.
Peer performance this week offers mild reassurance: UFPI, LPX, MAS, and CSL all gained 3-5% on the week, suggesting sector-level sentiment has lifted across building products names. BLDR's 5.6% weekly gain keeps pace with that move.
Tomorrow's print will test whether management can frame a credible path to earnings recovery in 2027 while delivering Q2 numbers that justify the tentative re-rating already underway.
See the live data behind this article on ORTEX.
Open BLDR on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
